Corporate Information – Page 24 – Alligator Bioscience

2018-08-30

Alligator Bioscience presents at the 20th Annual Rodman & Renshaw Global Investment Conference

Lund, Sweden, August 30 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals ...

2018-07-19

Regulatory

Lund, Sweden, July 19, 2018 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceutic ...

2018-06-25

To read the whole magazine, open the PDF-file at the bottom of this email.

2018-06-21

– Further preclinical findings support a best-in-class profile – Oral presentation at World Preclinical Congress, ...

2018-05-29

Meet the future of antibody-based immuno-oncology drugs Lund, Sweden, May 29, 2018 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a ...

2018-05-16

Meet the future of antibody-based immuno-oncology drugs Lund, Sweden, May 16, 2018 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a ...

2018-05-08

ALG.APV-527 is Designed to Strategically Target and Engage the Immune System for the Potential Treatment of Multiple Solid Tumor Indications ...

2018-05-03

– Unique binding profile and cross-linking properties – Oral presentation at Protein Engineering Summit in Boston, ...

2018-04-26

Lund, Sweden, 26 April 2018 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceutic ...